A Phase II Trial of D-Trp-6-LHRH (Decapeptyl) in Pretreated Patients with Advanced Epithelial Ovarian Cancer
作者:
RonIlan G.,
WiglerNely,
MerimskyOfer,
InbarMoshe J.,
ChaitchikSamario,
期刊:
Cancer Investigation
(Taylor Available online 1995)
卷期:
Volume 13,
issue 3
页码: 272-275
ISSN:0735-7907
年代: 1995
DOI:10.3109/07357909509094461
出版商: Taylor&Francis
数据来源: Taylor
摘要:
Fourteen patients with advanced ovarian cancer who failed chemotherapy received a long-acting LHRH agonist. All the patients had been previously operated on and all had received at least one regimen of chemotherapy. Duration of decapeptyl administration was between 1 month and 28 weeks. There were no complete or partial responses. Eight patients (57%) had disease stabilization with a median progressionfree interval of 14 weeks (range 4–28 weeks). All other patients developed a clear progressive cancer after the first injection of LHRH agonist. Three of these patients are still alive and receiving other forms of chemotherapy (median follow-up after rhe end of LHRH treatment was 11.5 months). The regimen was well tolerated with only mild toxicity observed (hot flushes in 2 patients). Although D-Trp-6-LHRH (Decapeptyl) was well tolerated, it had insignificant activity in treating patients with epithelial cancer that was resistant or relapsed after first-line platinum-based chemotherapy.
点击下载:
PDF (279KB)
返 回